Developing treatment options for metachromatic leukodystrophy

Molecular Genetics and Metabolism

Volumn 105, Issue 1, 2012, Pages 56-63

  Batzios, Spyros P ^a   Zafeiriou, Dimitrios I ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

Author keywords

Cell based gene therapy; Enzyme replacement therapy; Gene therapy; Hematopoietic stem cell transplantation; Metachromatic leukodystrophy

Indexed keywords

SOMATOMEDIN B RECEPTOR; VIRUS VECTOR;

ADJUVANT THERAPY; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW TRANSPLANTATION; CELL DIFFERENTIATION; CELL THERAPY; CLINICAL EFFECTIVENESS; CLINICAL TRIAL (TOPIC); CORD BLOOD STEM CELL TRANSPLANTATION; EMBRYONIC STEM CELL; ENZYME REPLACEMENT; FIRST TRIMESTER PREGNANCY; FOLLOW UP; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INTRACEREBRAL GENE THERAPY; INTRAUTERINE BLOOD TRANSFUSION; MESENCHYMAL STEM CELL TRANSPLANTATION; METACHROMATIC LEUKODYSTROPHY; MORBIDITY; MORTALITY; MULTICENTER STUDY (TOPIC); NEURAL STEM CELL TRANSPLANTATION; NONHUMAN; OLIGODENDROGLIA; PATIENT SAFETY; PHENOTYPIC PLASTICITY; PRIORITY JOURNAL; RETREATMENT; REVIEW; SCHWANN CELL; TREATMENT OUTCOME; VIRAL GENE THERAPY;

ANIMALS; CORD BLOOD STEM CELL TRANSPLANTATION; ENZYME REPLACEMENT THERAPY; GENE THERAPY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LEUKODYSTROPHY, METACHROMATIC; MESENCHYMAL STEM CELLS;

ANIMALIA;

EID: 84855354899     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.10.002     Document Type: Review

References (133)

1. Ozbayraktar F.B., Ulgen K.O. Molecular facets of sphingolipids: mediators of diseases. Biotechnol. J. 2009, 4:1028-1041.
2. Marcus J., Honigbaum S., Shroff S., Honke K., Rosenbluth J., Dupree J.L. Sulfatide is essential for the maintenance of CNS myelin and axon structure. Glia 2006, 53:372-381.
3. Gieselmann V., Krägeloh-Mann I. Metachromatic leukodystrophy - an update. Neuropediatrics 2010, 41:1-6.
4. Gieselmann V. Metachromatic leukodystrophy: genetics, pathogenesis and therapeutic options. Acta Paediatr. Suppl. 2008, 97:15-21.
5. Biffi A., Lucchini G., Rovelli A., Sessa M. Metachromatic leukodystrophy: an overview of current and prospective treatments. Bone Marrow Transplant. 2008, 42:2-6.
6. Kreysing J., von Figura K., Gieselmann V. Structure of the arylsulfatase A gene. Eur. J. Biochem. 1990, 191:627-631.
7. Hess B., Saftig P., Hartmann D., Coenen R., Lüllmann-Rauch R., Goebel H.H., Evers M., von Figura K., D'Hooge R., Nagels G., De Deyn P., Peters C., Gieselmann V. Phenotype of arylsulfatase A-deficient mice: relationship to human metachromatic leukodystrophy. Proc. Natl. Acad. Sci. U. S. A. 1996, 93:14821-14826.
8. Fratantoni J.C., Hall C.W., Neufeld E.F. Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 1968, 162:570-572.
9. Brazelton T.R., Rossi F.M.V., Keshet G.I., Blau H.M. From marrow to brain: expression of neuronal phenotypes in adult mice. Science 2000, 290:1775-1779.
10. Mezey E., Chandross K.J., Harta G., Maki R.A., McKercher S.R. Turning blood into brain: cells bearing neuronal antigens generated in vivo from bone marrow. Science 2000, 290:1779-1782.
11. Mezey E., Key S., Vogelsang G., Szalayova I., Lange G.D., Crain B. Transplanted bone marrow generates new neurons in human brains. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:1364-1369.
12. Weimann J.M., Charlton C.A., Brazelton T., Hackman R.C., Blau H.M. Contribution of transplanted bone marrow cells to Purkinje cells in human adult brains. Proc. Natl. Acad. Sci. U. S. A. 2003, 100:2088-2093.
13. Asheuer M., Pflumio F., Benhamida S., Dubart-Kupperschmitt A., Fouquet F., Imai Y., Aubourg P., Cartier N. Human CD34+ cells differentiate into microglia and express recombinant therapeutic protein. Proc. Natl. Acad. Sci. U. S. A. 2004, 101:3557-3562.
14. Porter M.T., Fluharty A.L., Kihara H. Correction of abnormal cerebroside sulfate metabolism in cultured metachromatic leukodystrophy fibroblasts. Science 1971, 172:1263-1265.
15. Bayever E., Ladisch S., Philippart M., Brill N., Nuwer M., Sparkes R.S., Feig S.A. Bone-marrow transplantation for metachromatic leucodystrophy. Lancet 1985, 2:471-473.
16. Peters C., Steward C.G. Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. 2003, 31:229-239. National Marrow Donor Program, International Bone Marrow Transplant RegistryInternational Bone Marrow Transplant Registry, Working Party on Inborn Errors, European Bone Marrow Transplant GroupWorking Party on Inborn Errors, European Bone Marrow Transplant Group.
17. Krivit W. Allogeneic stem cell transplantation for the treatment of lysosomal and peroxisomal metabolic diseases. Springer Semin. Immunopathol. 2004, 26:119-132.
18. Kidd D., Nelson J., Jones F., Dusoir H., Wallace I., McKinstry S., Patterson V. Long-term stabilization after bone marrow transplantation in juvenile metachromatic leukodystrophy. Arch. Neurol. 1998, 55:98-99.
19. Görg M., Wilck W., Granitzny B., Suerken A., Lukacs Z., Ding X., Schulte-Markwort M., Kohlschütter A. Stabilization of juvenile metachromatic leukodystrophy after bone marrow transplantation: a 13-year follow-up. J. Child Neurol. 2007, 22:1139-1142.
20. Navarro C., Fernández J.M., Domínguez C., Fachal C., Alvarez M. Late juvenile metachromatic leukodystrophy treated with bone marrow transplantation; a 4-year follow-up study. Neurology 1996, 46:254-256.
21. Malm G., Ringdén O., Winiarski J., Gröndahl E., Uyebrant P., Eriksson U., Håkansson H., Skjeldal O., Månsson J.E. Clinical outcome in four children with metachromatic leukodystrophy treated by bone marrow transplantation. Bone Marrow Transplant. 1996, 17:1003-1008.
22. Solders G., Celsing G., Hagenfeldt L., Ljungman P., Isberg B., Ringdén O. Improved peripheral nerve conduction, EEG and verbal IQ after bone marrow transplantation for adult metachromatic leukodystrophy. Bone Marrow Transplant. 1998, 22:1119-1122.
23. Ringdén O., Remberger M., Svahn B.M., Barkholt L., Mattsson J., Aschan J., Le Blanc K., Gustafsson B., Hassan Z., Omazic B., Svenberg P., Solders G., von Döbeln U., Winiarski J., Ljungman P., Malm G. Allogeneic hematopoietic stem cell transplantation for inherited disorders: experience in a single center. Transplantation 2006, 81:718-725.
24. Krivit W., Peters C., Shapiro E.G. Bone marrow transplantation as effective treatment of central nervous system disease in globoid cell leukodystrophy, metachromatic leukodystrophy, adrenoleukodystrophy, mannosidosis, fucosidosis, aspartylglucosaminuria, Hurler, Maroteaux-Lamy, and Sly syndromes, and Gaucher disease type III. Curr. Opin. Neurol. 1999, 12:167-176.
25. Smith N.J., Marcus R.E., Sahakian B.J., Kapur N., Cox T.M. Haematopoietic stem cell transplantation does not retard disease progression in the psycho-cognitive variant of late-onset metachromatic leukodystrophy. J. Inherit. Metab. Dis. 2010, (Nov 16, Electronic publication ahead of print). doi:10.1007/s10545-010-9240-1.
26. Kapaun P., Dittmann R.W., Granitzny B., Eickhoff W., Wulbrand H., Neumaier-Probst E., Zander A., Kohlschüetter A. Slow progression of juvenile metachromatic leukodystrophy 6years after bone marrow transplantation. J. Child Neurol. 1999, 14:222-228.
27. Pridjian G., Humbert J., Willis J., Shapira E. Presymptomatic late-infantile metachromatic leukodystrophy treated with bone marrow transplantation. J. Pediatr. 1994, 125:755-758.
28. Shapiro E.G., Lockman L.A., Balthazor M., Krivit W. Neuropsychological outcomes of several storage diseases with and without bone marrow transplantation. J. Inherit. Metab. Dis. 1995, 18:413-429.
29. Krivit W., Lockman L.A., Watkins P.A., Hirsch J., Shapiro E.G. The future for treatment by bone marrow transplantation for adrenoleukodystrophy, metachromatic leukodystrophy, globoid cell leukodystrophy and Hurler syndrome. J. Inherit. Metab. Dis. 1995, 18:398-412.
30. Krivit W., Lipton M.E., Lockman L.A., Tsai M., Dyck P.J., Smith S., Ramsay N.K., Kersey J. Prevention of deterioration in metachromatic leukodystrophy by bone marrow transplantation. Am. J. Med. Sci. 1987, 294:80-85.
31. Krivit W., Shapiro E., Kennedy W., Lipton M., Lockman L., Smith S., Summers C.G., Wenger D.A., Tsai M.Y., Ramsay N.K., et al. Treatment of late infantile metachromatic leukodystrophy by bone marrow transplantation. N. Engl. J. Med. 1990, 322:28-32.
32. Nagai T., Kaneko T., Shichijou H., Karato T., Maruyama A., Tsuchiya Y. Bone marrow transplantation for late infantile metachromatic leukodystrophy: pathogenic investigation for graft rejection. Acta Paediatr. Jpn. 1993, 35:404-408.
33. Bredius R.G., Laan L.A., Lankester A.C., Poorthuis B.J., van Tol M.J., Egeler R.M., Arts W.F. Early marrow transplantation in a pre-symptomatic neonate with late infantile metachromatic leukodystrophy does not halt disease progression. Bone Marrow Transplant. 2007, 39:309-310.
34. Gaipa G., Dassi M., Perseghin P., Venturi N., Corti P., Bonanomi S., Balduzzi A., Longoni D., Uderzo C., Biondi A., Masera G., Parini R., Bertagnolio B., Uziel G., Peters C., Rovelli A. Allogeneic bone marrow stem cell transplantation following CD34+ immunomagnetic enrichment in patients with inherited metabolic storage diseases. Bone Marrow Transplant. 2003, 31:857-860.
35. Shields L.E., Lindton B., Andrews R.G., Westgren M. Fetal hematopoietic stem cell transplantation: a challenge for the twenty-first century. J. Hematother. Stem Cell Res. 2002, 11:617-631.
36. Slavin S., Naparstek E., Ziegler M., Lewin A. Clinical application of intrauterine bone marrow transplantation for treatment of genetic diseases - feasibility studies. Bone Marrow Transplant. 1992, 9:189-190.
37. Accessed on 08/07/2011. http://clinicaltrials.gov/ct2/show/NCT00383448?term=metachromatic+leukodystrophy&rank=8.
38. Accessed on 08/07/2011. http://clinicaltrials.gov/ct2/show/NCT00004378?term=metachromatic+leukodystrophy&rank=10.
39. Accessed on 08/07/2011. http://clinicaltrials.gov/ct2/show/NCT00176904?term=metachromatic+leukodystrophy&rank=11.
40. Lanfranchi A., Porta F., Chirico G. Stem cells and the frontiers of neonatology. Early Hum. Dev. 2009, 85:15-18.
41. Kurtzberg J., Laughlin M., Graham M.L., Smith C., Olson J.F., Halperin E.C., Ciocci G., Carrier C., Stevens C.E., Rubinstein P. Placental blood as a source of hematopoietic stem cells for transplantation into unrelated recipients. N. Engl. J. Med. 1996, 335:157-166.
42. Wagner J.E., Rosenthal J., Sweetman R., Shu X.O., Davies S.M., Ramsay N.K., McGlave P.B., Sender L., Cairo M.S. Successful transplantation of HLA-matched and HLA-mismatched umbilical cord blood from unrelated donors: analysis of engraftment and acute graft-versus-host disease. Blood 1996, 88:795-802.
43. Wagner J.E., Kurtzberg J. Cord blood stem cells. Curr. Opin. Hematol. 1997, n4:413-418.
44. Martin P.L., Carter S.L., Kernan N.A., Sahdev I., Wall D., Pietryga D., Wagner J.E., Kurtzberg J. Results of the cord blood transplantation study (COBLT): outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with lysosomal and peroxisomal storage diseases. Biol. Blood Marrow Transplant. 2006, 12:184-194.
45. Boelens J.J. Trends in haematopoietic cell transplantation for inborn errors of metabolism. J. Inherit. Metab. Dis. 2006, 29:413-420.
46. Gluckman E., Rocha V., Chevret S. Results of unrelated umbilical cord blood hematopoietic stem cell transplant. Transfus. Clin. Biol. 2001, 8:146-154.
47. deGasperi R., Raghavan S.S., Sosa M.G., Kolodny E.H., Carrier C., Rubenstein P., Peters C., Wagner J., Kurtzberg J., Krivit W. Measurements from normal umbilical cord blood of four lysosomal enzymatic activities: alpha-l-iduronidase (Hurler), galactocerebrosidase (globoid cell leukodystrophy), arylsulfatase A (metachromatic leukodystrophy), arylsulfatase B (Maroteaux-Lamy). Bone Marrow Transplant 2000, 25:541-544.
48. Georgeson G.D., Szöny B.J., Streitman K., Sallay E., Kovács A., Kovács L., László A. Arylsulfatase-A in umbilical cord blood: gestational age and mode of delivery do not influence enzyme activity. Bone Marrow Transplant. 2002, 29:487-490.
49. Pierson T.M., Bonnemann C.G., Finkel R.S., Bunin N., Tennekoon G.I. Umbilical cord blood transplantation for juvenile metachromatic leukodystrophy. Ann. Neurol. 2008, 64:583-587.
50. Martin H.P., Poe M.D., Szabolcs P., Martin P., Suhag P., Vinod P., Joanne K., Maria E.L. Neurodevelopmental outcomes of unrelated umbilical cord transplantation for metachromatic leukodystrophy. Biol. Blood Marrow Transplant. 2007, 13(Suppl. S):63. (abstract 168).
51. Cable C., Finkel R.S., Lehky T.J., Biassou N.M., Wiggs E.A., Bunin N., Pierson T.M. Unrelated umbilical cord blood transplant for juvenile metachromatic leukodystrophy: a 5-year follow-up in three affected siblings. Mol. Genet. Metab. 2011, 102:207-209.
52. Escolar M.L., Poe M.D., Provenzale J.M., Richards K.C., Allison J., Wood S., Wenger D.A., Pietryga D., Wall D., Champagne M., Morse R., Krivit W., Kurtzberg J. Transplantation of umbilical-cord blood in babies with infantile Krabbe's disease. N. Engl. J. Med. 2005, 352:2069-2081.
53. Tokimasa S., Ohta H., Takizawa S., Kusuki S., Hashii Y., Sakai N., Taniike M., Ozono K., Hara J. Umbilical cord-blood transplantations from unrelated donors in patients with inherited metabolic diseases: single-institute experience. Pediatr. Transplant. 2008, 12:672-676.
54. Accessed on 09/07/2011. http://clinicaltrials.gov/ct2/show/NCT01003912?term=metachromatic+leukodystrophy&rank=14.
55. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 2003, 101:3722-3729.
56. Giordano A., Galderisi U., Marino I.R. From the laboratory bench to the patient's bedside: an update on clinical trials with mesenchymal stem cells. J. Cell. Physiol. 2007, 211:27-35.
57. Jori F.P., Napolitano M.A., Melone M.A., Cipollaro M., Cascino A., Altucci L., Peluso G., Giordano A., Galderisi U. Molecular pathways involved in neural in vitro differentiation of marrow stromal stem cells. J. Cell. Biochem. 2005, 94:645-655.
58. Beyer Nardi N., da Silva Meirelles L. Mesenchymal stem cells: isolation, in vitro expansion and characterization. Handb. Exp. Pharmacol. 2006, 174:249-282.
59. Kopen G.C., Prockop D.J., Phinney D.G. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc. Natl. Acad. Sci. U. S. A. 1999, 96:10711-10716.
60. Tropel P., Platet N., Platel J.C., Noel D., Albrieux M., Benabid A.L., Berger F. Functional neuronal differentiation of bone marrow-derived mesenchymal stem cells. Stem Cells 2006, 24:2868-2876.
61. Tondreau T., Lagneaux L., Dejeneffe M., Massy M., Mortier C., Delforge A., Bron D. Bone marrow-derived mesenchymal stem cells already express specific neural proteins before any differentiation. Differentiation 2004, 72:319-326.
62. Pittenger M.F., Mackay A.M., Beck S.C., Jaiswal R.K., Douglas R., Mosca J.D., Moorman M.A., Simonetti D.W., Craig S., Marshak D.R. Multilineage potential of adult human mesenchymal stem cells. Science 1999, 284:143-147.
63. Almeida-Porada G., Zanjani E.D. A large animal noninjury model for study of human stem cell plasticity. Blood Cells Mol. Dis. 2004, 32:77-81.
64. McBride C., Gaupp D., Phinney D.G. Quantifying levels of transplanted murine and human mesenchymal stem cells in vivo by real-time PCR. Cytotherapy 2003, 5:7-18.
65. Wang L., Li Y., Chen J., Gautam S.C., Zhang Z., Lu M., Chopp M. Ischemic cerebral tissue and MCP-1 enhance rat bone marrow stromal cell migration in interface culture. Exp. Hematol. 2002, 30:831-836.
66. François S., Bensidhoum M., Mouiseddine M., Mazurier C., Allenet B., Semont A., Frick J., Saché A., Bouchet S., Thierry D., Gourmelon P., Gorin N.C., Chapel A. Local irradiation not only induces homing of human mesenchymal stem cells at exposed sites but promotes their widespread engraftment to multiple organs: a study of their quantitative distribution after irradiation damage. Stem Cells 2006, 24:1020-1029.
67. Prockop D.J. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997, 276:71-74.
68. Müller I., Kustermann-Kuhn B., Holzwarth C., Isensee G., Vaegler M., Harzer K., Krägeloh-Mann I., Handgretinger R., Bruchelt G. In vitro analysis of multipotent mesenchymal stromal cells as potential cellular therapeutics in neurometabolic diseases in pediatric patients. Exp. Hematol. 2006, 34:1413-1419.
69. Koç O.N., Peters C., Aubourg P., Raghavan S., Dyhouse S., DeGasperi R., Kolodny E.H., Yoseph Y.B., Gerson S.L., Lazarus H.M., Caplan A.I., Watkins P.A., Krivit W. Bone marrow-derived mesenchymal stem cells remain host-derived despite successful hematopoietic engraftment after allogeneic transplantation in patients with lysosomal and peroxisomal storage diseases. Exp. Hematol. 1999, 27:1675-1681.
70. Meuleman N., Vanhaelen G., Tondreau T., Lewalle P., Kwan J., Bennani J., Martiat P., Lagneaux L., Bron D. Reduced intensity conditioning haematopoietic stem cell transplantation with mesenchymal stromal cells infusion for the treatment of metachromatic leukodystrophy: a case report. Haematologica 2008, 93:11-13.
71. Koç O.N., Day J., Nieder M., Gerson S.L., Lazarus H.M., Krivit W. Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 2002, 30:215-222.
72. Bae J.S., Furuya S., Shinoda Y., Endo S., Schuchman E.H., Hirabayashi Y., Jin H.K. Neurodegeneration augments the ability of bone marrow-derived mesenchymal stem cells to fuse with Purkinje neurons in Niemann-Pick type C mice. Hum. Gene Ther. 2005, 16:1006-1011.
73. Jin H.K., Schuchman E.H. Ex vivo gene therapy using bone marrow-derived cells: combined effects of intracerebral and intravenous transplantation in a mouse model of Niemann-Pick disease. Mol. Ther. 2003, 8:876-885.
74. Willingham M.C., Pastan I.H., Sahagian G.G., Jourdian G.W., Neufeld E.F. Morphologic study of the internalization of a lysosomal enzyme by the mannose 6-phosphate receptor in cultured Chinese hamster ovary cells. Proc. Natl. Acad. Sci. U. S. A. 1981, 78:6967-6971.
75. Ghosh P., Dahms N.M., Kornfeld S. Mannose 6-phosphate receptors: new twists in the tale. Nat. Rev. Mol. Cell Biol. 2003, 4:202-212.
76. Beck M. Therapy for lysosomal storage disorders. IUBMB Life 2010, 62:33-40.
77. Sevin C., Aubourg P., Cartier N. Enzyme, cell and gene-based therapies for metachromatic leukodystrophy. J. Inherit. Metab. Dis. 2007, 30:175-183.
78. Roces D.P., Lüllmann-Rauch R., Peng J., Balducci C., Andersson C., Tollersrud O., Fogh J., Orlacchio A., Beccari T., Saftig P., von Figura K. Efficacy of enzyme replacement therapy in alpha-mannosidosis mice: a preclinical animal study. Hum. Mol. Genet. 2004, 13:1979-1988.
79. Blanz J., Stroobants S., Lüllmann-Rauch R., Morelle W., Lüdemann M., D'Hooge R., Reuterwall H., Michalski J.C., Fogh J., Andersson C., Saftig P. Reversal of peripheral and central neural storage and ataxia after recombinant enzyme replacement therapy in alpha-mannosidosis mice. Hum. Mol. Genet. 2008, 17:3437-3445.
80. Vogler C., Levy B., Grubb J.H., Galvin N., Tan Y., Kakkis E., Pavloff N., Sly W.S. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. U. S. A. 2005, 102:14777-14782.
81. Matzner U., Herbst E., Hedayati K.K., Lüllmann-Rauch R., Wessig C., Schröder S., Eistrup C., Möller C., Fogh J., Gieselmann V. Enzyme replacement improves nervous system pathology and function in a mouse model for metachromatic leukodystrophy. Hum. Mol. Genet. 2005, 14:1139-1152.
82. Matzner U., Matthes F., Weigelt C., Andersson C., Eistrup C., Fogh J., Gieselmann V. Non-inhibitory antibodies impede lysosomal storage reduction during enzyme replacement therapy of a lysosomal storage disease. J. Mol. Med. (Berl.) 2008, 86:433-442.
83. Matzner U., Matthes F., Herbst E., Lüllmann-Rauch R., Callaerts-Vegh Z., D'Hooge R., Weigelt C., Eistrup C., Fogh J., Gieselmann V. Induction of tolerance to human arylsulfatase A in a mouse model of metachromatic leukodystrophy. Mol. Med. 2007, 13:471-479.
84. Matzner U., Lüllmann-Rauch R., Stroobants S., Andersson C., Weigelt C., Eistrup C., Fogh J., D'Hooge R., Gieselmann V. Enzyme replacement improves ataxic gait and central nervous system histopathology in a mouse model of metachromatic leukodystrophy. Mol. Ther. 2009, 17:600-606.
85. Stroobants S., Gerlach D., Matthes F., Hartmann D., Fogh J., Gieselmann V., D'Hooge R., Matzner U. Intracerebroventricular enzyme infusion corrects central nervous system pathology and dysfunction in a mouse model of metachromatic leukodystrophy. Hum. Mol. Genet. 2011, 20:2760-2769.
86. Martino S., Consiglio A., Cavalieri C., Tiribuzi R., Costanzi E., Severini G.M., Emiliani C., Bordignon C., Orlacchio A. Expression and purification of a human, soluble arylsulfatase A for metachromatic leukodystrophy enzyme replacement therapy. J. Biotechnol. 2005, 117:243-251.
87. Matthes F., Wölte P., Böckenhoff A., Hüwel S., Schulz M., Hyden P., Fogh J., Gieselmann V., Galla H.J., Matzner U. Transport of arylsulfatase A across the blood-brain barrier in vitro. J. Biol. Chem. 2011, 286:17487-17494.
88. Greene H.L., Hug G., Schubert W.K. Metachromatic leukodystrophy. Treatment with arylsulfatase-A. Arch. Neurol. 1969, 20:147-153.
89. accessed on 09/07/2011. http://clinicaltrials.gov/ct2/show/NCT00633139?term=metachromatic+leukodystrophy&rank=3.
90. accessed on 09/07/2011. http://clinicaltrials.gov/ct2/show/NCT01303146?term=metachromatic+leukodystrophy&rank=5.
91. accessed on 09/07/2011. http://clinicaltrials.gov/ct2/show/NCT00418561?term=metachromatic+leukodystrophy&rank=7.
92. Dali C.i, Lund A.M. Intravenous enzyme replacement therapy for metachromatic leukodystrophy (MLD). ACMG Meeting March 25 2009, American College of Medical Genetics, Tampa, USA (abstracts).
93. Sevin C., Verot L., Benraiss A., Van Dam D., Bonnin D., Nagels G., Fouquet F., Gieselmann V., Vanier M.T., De Deyn P.P., Aubourg P., Cartier N. Partial cure of established disease in an animal model of metachromatic leukodystrophy after intracerebral adeno-associated virus-mediated gene transfer. Gene Ther. 2007, 14:405-414.
94. Sevin C., Benraiss A., Van Dam D., Bonnin D., Nagels G., Verot L., Laurendeau I., Vidaud M., Gieselmann V., Vanier M., De Deyn P.P., Aubourg P., Cartier N. Intracerebral adeno-associated virus-mediated gene transfer in rapidly progressive forms of metachromatic leukodystrophy. Hum. Mol. Genet. 2006, 15:53-64.
95. Kurai T., Shimada T. Recombinant adeno-associated virus-mediated gene delivery to the central nervous system. J. Nippon Med. Sch. 2007, 74:188-189.
96. Kurai T., Hisayasu S., Kitagawa R., Migita M., Suzuki H., Hirai Y., Shimada T. AAV1 mediated co-expression of formylglycine-generating enzyme and arylsulfatase a efficiently corrects sulfatide storage in a mouse model of metachromatic leukodystrophy. Mol. Ther. 2007, 15:38-43.
97. Colle M.A., Piguet F., Bertrand L., Raoul S., Bieche I., Dubreil L., Sloothaak D., Bouquet C., Moullier P., Aubourg P., Cherel Y., Cartier N., Sevin C. Efficient intracerebral delivery of AAV5 vector encoding human ARSA in non-human primate. Hum. Mol. Genet. 2010, 19:147-158.
98. Lattanzi A., Neri M., Maderna C., di Girolamo I., Martino S., Orlacchio A., Amendola M., Naldini L., Gritti A. Widespread enzymatic correction of CNS tissues by a single intracerebral injection of therapeutic lentiviral vector in leukodystrophy mouse models. Hum. Mol. Genet. 2010, 19:2208-2227.
99. Consiglio A., Quattrini A., Martino S., Bensadoun J.C., Dolcetta D., Trojani A., Benaglia G., Marchesini S., Cestari V., Oliverio A., Bordignon C., Naldini L. In vivo gene therapy of metachromatic leukodystrophy by lentiviral vectors: correction of neuropathology and protection against learning impairments in affected mice. Nat. Med. 2001, 7:310-316.
100. Luca T., Givogri M.I., Perani L., Galbiati F., Follenzi A., Naldini L., Bongarzone E.R. Axons mediate the distribution of arylsulfatase A within the mouse hippocampus upon gene delivery. Mol. Ther. 2005, 12:669-679.
101. Matzner U., Habetha M., Gieselmann V. Retrovirally expressed human arylsulfatase A corrects the metabolic defect of arylsulfatase A-deficient mouse cells. Gene Ther. 2000, 7:805-812.
102. Maria B.L., Deidrick K.M., Moser H., Naidu S. Leukodystrophies: pathogenesis, diagnosis, strategies, therapies, and future research directions. J. Child Neurol. 2003, 18:578-590.
103. D'Hooge R., Hartmann D., Manil J., Colin F., Gieselmann V., De Deyn P.P. Neuromotor alterations and cerebellar deficits in aged arylsulfatase A-deficient transgenic mice. Neurosci. Lett. 1999, 273:93-96.
104. Wittke D., Hartmann D., Gieselmann V., Lüllmann-Rauch R. Lysosomal sulfatide storage in the brain of arylsulfatase A-deficient mice: cellular alterations and topographic distribution. Acta Neuropathol. 2004, 108:261-271.
105. Cunningham J., Pivirotto P., Bringas J., Suzuki B., Vijay S., Sanftner L., Kitamura M., Chan C., Bankiewicz K.S. Biodistribution of adeno-associated virus type-2 in nonhuman primates after convection-enhanced delivery to brain. Mol. Ther. 2008, 16:1267-1275.
106. Iwamoto N., Watanabe A., Yamamoto M., Miyake N., Kurai T., Teramoto A., Shimada T. Global diffuse distribution in the brain and efficient gene delivery to the dorsal root ganglia by intrathecal injection of adeno-associated viral vector serotype 1. J. Gene Med. 2009, 11:498-505.
107. Cosma M.P., Pepe S., Annunziata I., Newbold R.F., Grompe M., Parenti G., Ballabio A. The multiple sulfatase deficiency gene encodes an essential and limiting factor for the activity of sulfatases. Cell 2003, 113:445-456.
108. Takakusaki Y., Hisayasu S., Hirai Y., Shimada T. Coexpression of formylglycine-generating enzyme is essential for synthesis and secretion of functional arylsulfatase A in a mouse model of metachromatic leukodystrophy. Hum. Gene Ther. 2005, 16:929-936.
109. Fraldi A., Biffi A., Lombardi A., Visigalli I., Pepe S., Settembre C., Nusco E., Auricchio A., Naldini L., Ballabio A., Cosma M.P. SUMF1 enhances sulfatase activities in vivo in five sulfatase deficiencies. Biochem. J. 2007, 403:305-312.
110. Sevin C., Roujeau T., Piguet F., Sondhi D., Colle M.A., Raoul S., Deschamps J.Y., Bouquet C., Vanier M., Moullier P., Cherel Y., Hackett N.R., Zerah M., Crystal R.G., Cartier N., Aubourg P. Brain gene therapy for metachromatic leukodystrophy: from bench to bedside. Eur. J. Paediatr. Neurol. 2011, 15(Suppl. 1):S50.
111. Tsutsuda-Asano A., Migita M., Takahashi K., Shimada T. Transduction of fibroblasts and CD34+ progenitors using a selectable retroviral vector containing cDNAs encoding arylsulfatase A and CD24. J. Hum. Genet. 2000, 45:18-23.
112. Ohashi T., Eto Y., Learish R., Barranger J.A. Correction of enzyme deficiency in metachromatic leukodystrophy fibroblasts by retroviral-mediated transfer of the human arylsulphatase A gene. J. Inherit. Metab. Dis. 1993, 16:881-885.
113. Sangalli A., Taveggia C., Salviati A., Wrabetz L., Bordignon C., Severini G.M. Transduced fibroblasts and metachromatic leukodystrophy lymphocytes transfer arylsulfatase A to myelinating glia and deficient cells in vitro. Hum. Gene Ther. 1998, 9:2111-2119.
114. Learish R., Ohashi T., Robbins P.A., Bahnson A., Boggs S.S., Patrene K., Schwartz B.E., Gieselmann V., Barranger J.A. Retroviral gene transfer and sustained expression of human arylsulfatase A. Gene Ther. 1996, 3:343-349.
115. Ohashi T., Watabe K., Sato Y., Saito I., Barranger J.A., Eto Y. Successful transduction of oligodendrocytes and restoration of arylsulfatase A deficiency in metachromatic leukodystrophy fibroblasts using an adenovirus vector. Gene Ther. 1995, 2:443-449.
116. Matzner U., Harzer K., Learish R.D., Barranger J.A., Gieselmann V. Long-term expression and transfer of arylsulfatase A into brain of arylsulfatase A-deficient mice transplanted with bone marrow expressing the arylsulfatase A cDNA from a retroviral vector. Gene Ther. 2000, 7:1250-1257.
117. Matzner U., Hartmann D., Lüllmann-Rauch R., Coenen R., Rothert F., Månsson J.E., Fredman P., D'Hooge R., De Deyn P.P., Gieselmann V. Bone marrow stem cell-based gene transfer in a mouse model for metachromatic leukodystrophy: effects on visceral and nervous system disease manifestations. Gene Ther. 2002, 9:53-63.
118. Biffi A., De Palma M., Quattrini A., Del Carro U., Amadio S., Visigalli I., Sessa M., Fasano S., Brambilla R., Marchesini S., Bordignon C., Naldini L. Correction of metachromatic leukodystrophy in the mouse model by transplantation of genetically modified hematopoietic stem cells. J. Clin. Invest. 2004, 113:1118-1129.
119. Biffi A., Capotondo A., Fasano S., del Carro U., Marchesini S., Azuma H., Malaguti M.C., Amadio S., Brambilla R., Grompe M., Bordignon C., Quattrini A., Naldini L. Gene therapy of metachromatic leukodystrophy reverses neurological damage and deficits in mice. J. Clin. Invest. 2006, 116:3070-3082.
120. Miyake N., Miyake K., Karlsson S., Shimada T. Successful treatment of metachromatic leukodystrophy using bone marrow transplantation of HoxB4 overexpressing cells. Mol. Ther. 2010, 18:1373-1378.
121. Capotondo A., Cesani M., Pepe S., Fasano S., Gregori S., Tononi L., Venneri M.A., Brambilla R., Quattrini A., Ballabio A., Cosma M.P., Naldini L., Biffi A. Safety of arylsulfatase A overexpression for gene therapy of metachromatic leukodystrophy. Hum. Gene Ther. 2007, 18:821-836.
122. accessed on 09/08/2011. http://www.mldfoundation.org/research-SanRaffaele.html.
123. Consiglio A., Martino S., Dolcetta D., Cusella G., Conese M., Marchesini S., Benaglia G., Wrabetz L., Orlacchio A., Déglon N., Aebischer P., Severini G.M., Bordignon C. Metabolic correction in oligodendrocytes derived from metachromatic leukodystrophy mouse model by using encapsulated recombinant myoblasts. J. Neurol. Sci. 2007, 255:7-16.
124. Lagranha V.L., Baldo G., de Carvalho T.G., Burin M., Saraiva-Pereira M.L., Matte U., Giugliani R. In vitro correction of ARSA deficiency in human skin fibroblasts from metachromatic leukodystrophy patients after treatment with microencapsulated recombinant cells. Metab. Brain Dis. 2008, 23:469-484.
125. Calver A.R., Hall A.C., Yu W.P., Walsh F.S., Heath J.K., Betsholtz C., Richardson W.D. Oligodendrocyte population dynamics and the role of PDGF in vivo. Neuron 1998, 20:869-882.
126. Redwine J.M., Armstrong R.C. In vivo proliferation of oligodendrocyte progenitors expressing PDGFalphaR during early remyelination. J. Neurobiol. 1998, 37:413-428.
127. Givogri M.I., Galbiati F., Fasano S., Amadio S., Perani L., Superchi D., Morana P., Del Carro U., Marchesini S., Brambilla R., Wrabetz L., Bongarzone E. Oligodendroglial progenitor cell therapy limits central neurological deficits in mice with metachromatic leukodystrophy. J. Neurosci. 2006, 26:3109-3119.
128. Reynolds B.A., Weiss S. Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. Science 1992, 255:1707-1710.
129. Kawabata K., Migita M., Mochizuki H., Miyake K., Igarashi T., Fukunaga Y., Shimada T. Ex vivo cell-mediated gene therapy for metachromatic leukodystrophy using neurospheres. Brain Res. 2006, 1094:13-23.
130. Givogri M.I., Bottai D., Zhu H.L., Fasano S., Lamorte G., Brambilla R., Vescovi A., Wrabetz L., Bongarzone E. Multipotential neural precursors transplanted into the metachromatic leukodystrophy brain fail to generate oligodendrocytes but contribute to limit brain dysfunction. Dev. Neurosci. 2008, 30:340-357.
131. Perez-Bouza, Glaser T., Brüstle O. ES cell-derived glial precursors contribute to remyelination in acutely demyelinated spinal cord lesions. Brain Pathol. 2005, 15:208-216.
132. Klein D., Schmandt T., Muth-Köhne E., Perez-Bouza A., Segschneider M., Gieselmann V., Brüstle O. Embryonic stem cell-based reduction of central nervous system sulfatide storage in an animal model of metachromatic leukodystrophy. Gene Ther. 2006, 13:1686-1695.
133. accessed on 09/07/2011. http://clinicaltrials.gov/ct2/show/NCT00683189?term=metachromatic+leukodystrophy&rank=6.